Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Emanuella Romano"'
Autor:
Joanna Mangana, Phil F Cheng, Katja Schindler, Benjamin Weide, Ulrike Held, Anna L Frauchiger, Emanuella Romano, Katharina C Kähler, Sima Rozati, Markus Rechsteiner, Holger Moch, Olivier Michielin, Claus Garbe, Axel Hauschild, Christoph Hoeller, Reinhard Dummer, Simone M Goldinger
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139438 (2015)
Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Current
Externí odkaz:
https://doaj.org/article/8b3f40cc8c594f6cb05ca30642659a43
Autor:
Axel Hauschild, Emanuella Romano, Benjamin Weide, Katja Schindler, Phil F. Cheng, Claus Garbe, Olivier Michielin, Katharina C. Kähler, Joanna Mangana, Simone M. Goldinger, Anna L. Frauchiger, Markus Rechsteiner, Christoph Hoeller, Reinhard Dummer, Ulrike Held, Holger Moch, Sima Rozati
Publikováno v:
Plos One, vol. 10, no. 10, pp. e0139438
PLoS ONE, Vol 10, Iss 10, p e0139438 (2015)
PLoS ONE
PLoS ONE, Vol 10, Iss 10, p e0139438 (2015)
PLoS ONE
Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20672d3e3976680be6f65fa4095cfd2
https://doi.org/10.5167/uzh-113447
https://doi.org/10.5167/uzh-113447